Product image of Linezolid Kabi (Linezolid) supplied by GNH India

Linezolid Kabi

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Kabi (Linezolid)

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injection solution for intravenous use. It treats serious bacterial infections such as skin and soft‑tissue infections, community‑acquired pneumonia, hospital‑acquired pneumonia, methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH India supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Fresenius Kabi D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is an oxazolidinone antibacterial indicated for several serious infections.

  • Skin and soft tissue infections: effective against Gram‑positive pathogens, reducing lesion size and bacterial load.
  • Community‑acquired pneumonia: improves clinical cure rates in adult patients with typical and atypical organisms.
  • Hospital‑acquired (nosocomial) pneumonia: provides coverage for resistant strains in intensive‑care settings.
  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers an alternative when beta‑lactams are ineffective.
  • Vancomycin‑resistant Enterococcus (VRE) infections: active against strains resistant to vancomycin, aiding infection control.

How It Works

  • Linezolid binds to the 50S ribosomal subunit of susceptible bacteria, preventing formation of the initiation complex for protein synthesis. This inhibition halts bacterial growth (bacteriostatic) against most Gram‑positive organisms and can be bactericidal at higher concentrations or against specific strains, thereby limiting infection progression.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, occasionally watery.
  • Headache: transient cranial discomfort.
  • Vomiting: occasional emesis.
  • Metallic taste: altered taste perception.
  • Rash: mild skin erythema.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count, requiring monitoring.
  • Anemia: reduced red blood cell levels, potentially causing fatigue.
  • Leukopenia: lowered white blood cell count, increasing infection risk.
  • Peripheral neuropathy: nerve pain or sensory changes, may be irreversible.
  • Serotonin syndrome: risk when combined with serotonergic agents.
  • Lactic acidosis: rare metabolic disturbance with high morbidity.

Precautions & Warnings

Clinicians should consider several safety measures before initiating therapy.

  • Renal impairment: adjust monitoring as renal function may affect drug clearance.
  • Hepatic impairment: use caution; liver dysfunction can alter metabolism.
  • Hematologic monitoring: perform regular blood counts to detect myelosuppression.
  • Concomitant serotonergic drugs: avoid or monitor closely due to serotonin syndrome risk.
  • Pregnancy & lactation: safety not established; weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Linezolid may interact with several medication classes.

Major Interactions (Avoid)

  • Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): risk of serotonin syndrome.
  • MAO inhibitors: potential hypertensive crisis.
  • Rifampin: induces metabolism, reducing linezolid exposure.
  • Anticoagulants (warfarin): may increase INR, enhancing bleeding risk.
  • Ethanol: may potentiate central nervous system depression.

Moderate Interactions (Monitor Closely)

  • NSAIDs: additive effect on bleeding risk.
  • Anticonvulsants (phenytoin, carbamazepine): may lower linezolid levels.
  • Digoxin: possible increase in serum concentration.
  • Oral contraceptives: monitor for reduced efficacy.
  • Immunosuppressants (cyclosporine): may require dose adjustment.

Frequently Asked Questions

Linezolid Kabi is indicated for serious bacterial infections including skin and soft‑tissue infections, community‑acquired pneumonia, hospital‑acquired pneumonia, infections caused by methicillin‑resistant Staphylococcus aureus (MRSA), and infections caused by vancomycin‑resistant Enterococcus (VRE). It is used in adult patients when these pathogens are identified or strongly suspected.

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the formation of the initiation complex required for translation. This action halts bacterial growth (bacteriostatic) against most Gram‑positive organisms and can be bactericidal at higher concentrations or against specific strains, thereby controlling the infection.

The specific dose and duration of Linezolid Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and adjust therapy as needed.

Safety data for linezolid in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks to the fetus or infant and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain handling if needed) and assist with import documentation.

Linezolid and vancomycin are both active against Gram‑positive bacteria, but linezolid is an oral and intravenous oxazolidinone, while vancomycin is a glycopeptide given intravenously. Linezolid offers convenient dosing and activity against some vancomycin‑resistant strains, whereas vancomycin may be preferred for certain severe infections. Choice depends on pathogen susceptibility, patient renal function, and clinical context.

Linezolid Kabi should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Maintaining the cold chain preserves drug stability and potency.

Linezolid Kabi is supplied as an injectable solution for intravenous infusion. The infusion is typically administered over a period defined by the prescribing clinician, often 30‑60 minutes, using aseptic technique and appropriate IV equipment. Dosage adjustments may be required based on renal or hepatic function.

Serious adverse events include thrombocytopenia, anemia, leukopenia, peripheral neuropathy, serotonin syndrome (especially when combined with serotonergic drugs), and lactic acidosis. Patients should be monitored regularly for hematologic changes and neurological symptoms, and clinicians should avoid concomitant serotonergic agents.

Linezolid Kabi should be avoided in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking serotonergic medications, MAO inhibitors, or those with significant bone‑marrow suppression. Pregnant or breastfeeding women should only use it if the potential benefit outweighs the unknown risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.